Ethosome for Enhanced Transdermal Drug Delivery of Aceclofenac
Keywords:
Ethosome, Aceclofenac, Phospholipid, TransdermalAbstract
The aim of the current investigation is to evaluate the transdermal potential of novel vesicular carrier, ethosomes, bearing aceclofenac, Non-steroidal antiinflammatory drugs (NSAIDs) agents having limited transdermal permeation. Aceclofenac loaded ethosomal carriers were prepared, optimized and characterized for vesicular shape and surface morphology,(SEM) scanning electronic microscopy, vesicular size, entrapment efficiency, stability, invitro release study. The formulation (Etho5) having 3% phospholipids contant and 40% ethanol showing the grater entrapment (93.3%) and optimal average vesicle size of formulation (Etho5) determine by Malvern Zetamaster ZEM & 0.696µm and zeta potential of formulation was -6.74 mV. The formulation (Etho12) having 3% phospholipids contant and 40% isopropyl alcohol showing the grater entrapment (95.7%). stability profile of prepared system assessed for 45 days. The vesicular suspension was kept in sealed vials (10ml) at 4 ± 2ºC and at room temperature for 45 days no change is shown in the entrapment efficiency. The optimized ethosomal formulation showed transdermal flux (226.1 µg/cm²/hr) for ethanolic drug solution which is grater then that of isopropyl alcohol solution (159.0 µg/cm²/hr). The result advocates the potential of ethosome formulation to treat rheumatic disease where facilitated penetration of the drug into muscle and synovial fluid is desirable. In light of the data obtained from experimental work we can expect the ethosome formulation to be safe and very efficient as a drug carrier for systemic as well as topical delivery of drug, holding future in effective transdermal delivery.
References
Touitou E, Merdan VM. Vesicular carriers for
topical delivery.Acta Technologiae et legis
Medicoment ; 1998; 91: 1-6
Touitou E, Dayan N, Bergelson L, Godin B, Eliaz
M. Ethosomes-novel vesicular carriers for
enhanced delivery: characterization and skin
penetration properties. J. Control. Release, 2000;
:403
Touitou, E. Composition of applying active
substance to or through the skin., US patent,
,5,716,638,
Touitou, E. Composition of applying active
substance to or through the skin., US patent,
,5,540,934,
Dubey V, Jain NK. Melatonin lodaded
liposomes:physicochemical characterization and
enhanced transdermal delivery. Euro J Pharm
; 67: 398-405.
Mishra AN, Jain NK. Transdermal drug delivery
system ,controlled and noval drug delivery
system, Edited by Jain N. K. (2007)
Klecker JT RW, Collitus JM. Clin. Pharmacol
; 41: 407.
Horwitz E, Pisanty S, Czerniski R, Touitou E.
Oral Surg.b Oral Med. Oral radiol.1999; 87: 700.
Jain S, Umamaheshwari RB, Bhadra D, Jain NK.
Ind. J. Pharm. Sci. 2004; 66: 72-81.
Jain S, Jain S, Jain NK. Transfersomes for
enhanced delivery of dexamethasone, Proceeding
of 28th Conference of CRS, USA, 2001, 5207.
Jain S, Jain S, Jain NK. Drug Delivery Tech.
; 2: 70-71.
Jain S, Jain P, Jain NK. Drug Dev. Ind. Pharm.
; 29: 1013-1026.
Jain S, Jain N, Bhadra D, Tiwary AK, Jain NK.
Sustained and targeted delivery of an analgesic
agent using ultradeformable lipid vesicles.
Proceeding of the 54rd Indian Pharmaceutical
conference, Pune (India), 2002: A-67
Jain S, Jain N, Bhadra D, Tiwary AK, Jain NK.
Curr Drug Del 2004; 2: 222-233
Jain S, Tiwary AK, Jain NK. Sustained and
targeted transdermal delivery of an anti-HIV
agent using elastic liposomal formulation:
Mechanism of action. Curr Drug Del 2005; 3:
-164
Touitou E, Godin B, Weiss C. Enhanced delivery
of drugs into and across the skin by ethosomal
carriers. Drug Develop Res 2000;50: 406 - 415
Touitou E, Godin B, Dayan N, Weiss C,
Piliponsky A. Levi-Schaffer F.; Intracellular
delivery mediated by an ethosomal carrier.
Biomaterials 2001; 22: 3053-3059
Dayan N, Touitou E. Carriers for skin delivery of
trihexyphenidyl HCI: ethosomes vs. liposomes.
Biomaterials 2000; 21: 1879-1885
Touitou E. Drug delivery across the skin. Biol.
Therm. 2002; 2: 723-733
